New research from scholars at Columbia Business School and the University of Pittsburgh questions the sustainability of Twitter, the social network that has more than 500 million registered users. The research was recently published in the journal Marketing Science.
Columbia Business School Professor Olivier Toubia has a thought-provoking, 140-character-limit comment about the research he co-authored with University of Pittsburgh’s Assistant Professor Andrew T. Stephen.
“Get ready for a TV-like Twitter,” said Toubia.
The research examined the motivations behind why everyday people, with no financial incentive, contribute to Twitter.
The study examined roughly 2500 non-commercial Twitter users. In a field experiment, Toubia and Stephens randomly selected some of those users and, through the use of other synthetic accounts, increased the selected group’s followers. At first, Toubia and Stephen noticed that as the selected group’s followers increased, so did the posting rate. However, when that group reached a level of stature — a moderately large amount of followers — the posting rate declined significantly.
“Users began to realize it was harder to continue to attract more followers with their current strategy, so they slowed down,” Toubia added. “When posting activity no longer leads to additional followers, people will view Twitter as a non-evolving, static structure, like TV.”
Based on the analyses, Toubia and Stephen predict Twitter posts by everyday people will slow down, yet celebrities and commercial users will continue to post for financial gain.
“Twitter will become less of a communications vehicle and more of a content-delivery vehicle, much like TV. Peer-to-peer contact is likely to evolve to the next great thing, but with 500 million followers, Twitter isn’t just going to disappear. It’s just going to become a new way to follow celebrities, corporations, and the like,” said Toubia.
Researchers have generated functional hepatocytes from human stem cells, transplanted them into mice with acute liver injury, and shown the ability of these stem-cell derived human liver cells to function normally and increase survival of the treated animals. This promising advance in the development of cell-based therapies to treat liver failure resulting from injury or disease relied on the development of scalable, reproducible methods to produce stem cell-derived hepatocytes in bioreactors